GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Cyclically Adjusted FCF per Share

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Cyclically Adjusted FCF per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Fusion Pharmaceuticals's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was $-1.306. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-25), Fusion Pharmaceuticals's current stock price is $ 21.48. Fusion Pharmaceuticals's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was $0.00. Fusion Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Fusion Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Fusion Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Fusion Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial - - - - -

Fusion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fusion Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Fusion Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Fusion Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fusion Pharmaceuticals's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.306/125.0724*125.0724
=-1.306

Current CPI (Dec. 2023) = 125.0724.

Fusion Pharmaceuticals does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Fusion Pharmaceuticals  (NAS:FUSN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Fusion Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Executives
Teresa Marie Bitetti director 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender director 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev officer: Chief Medical Officer C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant director, officer: Chief Executive Officer FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon officer: Chief Scientific Officer C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat officer: President and CBO FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom director 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee director C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley officer: Chief Financial Officer 251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p. 10 percent owner 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary officer: Chief Medical Officer 830 WINTER STREET, WALTHAM MA 02452